Review of selected patents for cancer therapy targeting tumor angiogenesis.
Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.
Kirstein
Mark N
MN
Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Moore
Megan M
MM
Dudek
Arkadiusz Z
AZ
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D043168:Angiostatins / Q000494:pharmacology / Q000502:physiology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D043169:Endostatins / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000150:complications / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D010330:Patents as Topic; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D042461:Vascular Endothelial Growth Factor A; D043168:Angiostatins